NCT00333216

Anecortave Acetate Risk-Reduction Trial (AART)

Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

Conditions

• AMD

Interventions

Type	Name	Description
DRUG	Anecortave Acetate Sterile Suspension, 30 mg/mL	Posterior juxtascleral administration of suspension
DRUG	Anecortave Acetate Sterile Suspension, 60 mg/ML	Posterior juxtascleral administration of suspension
OTHER	Anecortave Acetate Vehicle	Sham posterior juxtascleral administration of suspension

Timeline

• Start date: 2005-05-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2006-06-02
• Last updated: 2012-11-28

Locations

1 site across 1 country: United States